These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

170 related items for PubMed ID: 36127853

  • 1. The need to tailor the omission of axillary lymph node dissection to patients with good prognosis and sentinel node micro-metastases.
    Houvenaeghel G, de Nonneville A, Chopin N, Classe JM, Mazouni C, Chauvet MP, Reyal F, Tunon de Lara C, Jouve E, Rouzier R, Daraï E, Gimbergues P, Coutant C, Azuar AS, Villet R, Crochet P, Rua S, Bannier M, Cohen M, Boher JM.
    Cancer Med; 2023 Feb; 12(4):4023-4032. PubMed ID: 36127853
    [Abstract] [Full Text] [Related]

  • 2. Eight-year follow up result of the OTOASOR trial: The Optimal Treatment Of the Axilla - Surgery Or Radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer: A randomized, single centre, phase III, non-inferiority trial.
    Sávolt Á, Péley G, Polgár C, Udvarhelyi N, Rubovszky G, Kovács E, Győrffy B, Kásler M, Mátrai Z.
    Eur J Surg Oncol; 2017 Apr; 43(4):672-679. PubMed ID: 28139362
    [Abstract] [Full Text] [Related]

  • 3. Overview of the pathological results and treatment characteristics in the first 1000 patients randomized in the SERC trial: axillary dissection versus no axillary dissection in patients with involved sentinel node.
    Houvenaeghel G, Cohen M, Raro P, De Troyer J, de Lara CT, Gimbergues P, Gauthier T, Faure-Virelizier C, Vaini-Cowen V, Lantheaume S, Regis C, Darai E, Ceccato V, D'Halluin G, Del Piano F, Villet R, Jouve E, Beedassy B, Theret P, Gabelle P, Zinzindohoue C, Opinel P, Marsollier-Ferrer C, Dhainaut-Speyer C, Colombo PE, Lambaudie E, Tallet A, Boher JM, Others investigators (SERC trial group).
    BMC Cancer; 2018 Nov 21; 18(1):1153. PubMed ID: 30463611
    [Abstract] [Full Text] [Related]

  • 4. Contemporary Axillary Management in cT1-2N0 Breast Cancer with One or Two Positive Sentinel Lymph Nodes: Factors Associated with Completion Axillary Lymph Node Dissection Within the National Cancer Database.
    Stafford AP, Hoskin TL, Day CN, Sanders SB, Boughey JC.
    Ann Surg Oncol; 2022 Aug 21; 29(8):4740-4749. PubMed ID: 35451727
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Comparing Observation, Axillary Radiotherapy, and Completion Axillary Lymph Node Dissection for Management of Axilla in Breast Cancer in Patients with Positive Sentinel Nodes: A Systematic Review.
    Castelo M, Hu SY, Dossa F, Acuna SA, Scheer AS.
    Ann Surg Oncol; 2020 Aug 21; 27(8):2664-2676. PubMed ID: 32020394
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Non-sentinel axillary tumor burden applying the ACOSOG Z0011 eligibility criteria to a large routine cohort.
    Riedel F, Heil J, Feißt M, Rezai M, Moderow M, Sohn C, Schütz F, Golatta M, Hennigs A.
    Breast Cancer Res Treat; 2019 Sep 21; 177(2):457-467. PubMed ID: 31236814
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Omission of Completion Axillary Lymph Node Dissection for Patients with Breast Cancer Treated by Upfront Mastectomy and Sentinel Node Isolated Tumor Cells or Micrometastases.
    Houvenaeghel G, Heinemann M, Classe JM, Bouteille C, Gimbergues P, Azuar AS, Martino M, Tallet A, Cohen M, de Nonneville A.
    Cancers (Basel); 2024 Jul 26; 16(15):. PubMed ID: 39123393
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Trends on Axillary Surgery in Nondistant Metastatic Breast Cancer Patients Treated Between 2011 and 2015: A Dutch Population-based Study in the ACOSOG-Z0011 and AMAROS Era.
    Poodt IGM, Spronk PER, Vugts G, van Dalen T, Peeters MTFDV, Rots ML, Kuijer A, Nieuwenhuijzen GAP, Schipper RJ.
    Ann Surg; 2018 Dec 26; 268(6):1084-1090. PubMed ID: 28742702
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Women Could Avoid Axillary Lymph Node Dissection by Choosing Breast-Conserving Therapy Instead of Mastectomy.
    Vane MLG, Hunter-Squires J, Kim S, Smidt ML, Giuliano AE.
    Ann Surg Oncol; 2021 May 26; 28(5):2522-2528. PubMed ID: 33586070
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Sentinel node positive breast cancer patients who do not undergo axillary dissection: are they different?
    Zakaria S, Pantvaidya G, Reynolds CA, Grant CS, Sterioff S, Donohue JH, Farley DR, Hoskin TL, Degnim AC.
    Surgery; 2008 May 26; 143(5):641-7. PubMed ID: 18436012
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Surgeon Bias in the Management of Positive Sentinel Lymph Nodes.
    Mathias BJ, Sun J, Sun W, Zhou JM, Fulp WJ, Laronga C, Lee MC, Kiluk JV.
    Clin Breast Cancer; 2021 Feb 26; 21(1):74-79. PubMed ID: 32917535
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.